leisure time -WSS

leisure time

author：hotspot 2025-10-01 12:35:09 - browse：8887

Illustration of a teal cancer cell. -- health coverage from STAT — Illustration of a teal cancer cell. Adobe

Sana Biotechnology, a startup that just a couple of years ago raised over $1 billion off a grand plan to create a portfolio of powerful medicines, said Tuesday it would lay off nearly a third of its employees and de-prioritize one of its most ambitious programs as it looks to save money.

The layoffs are Sana’s second round of cuts in less than a year. It laid off 15% of staff last November after axing another program.

Tuesday’s move pushed back a program focused on turning a patient’s own immune cells into cancer-killing assassins or curing blood disorders such as sickle cell with just an IV infusion. Known as in vivo reprogramming, it was originally the company’s central focus and would have amounted to a monumental breakthrough.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： A cyberattack has disrupted hospitals and health care in several states

explore

WSS

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Humana, CVS hope to turn members into patients at clinics

2 US Navy sailors arrested for allegedly spying for China

Regeneron agrees to White House price limits on anti

ProMED, early warning system on disease outbreaks, in peril

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Wikipedia

leisure time

focus

Medical records are filled with copy

Food makers tried to stack nutrition panel with preferred experts

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

The high cost of giving birth even with insurance

Pig kidney works a record two months in donated body

BioMarin wins approval for gene therapy to treat hemophilia A

Long Covid needs a new name — and a new frame

Medicare details structure of new drug price negotiation program

TytoCare raises $49 million to build out AI

focus

Biden calls for immediate release of Niger's president amid apparent coup

What Henrietta Lacks settlement says about racism in medicine

'Ancient DNA,' 23andMe reveal African American ancestries

What to make of Biden’s latest efforts on cancer research

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Attacks on the drug industry will lead to fewer breakthroughs

knowledge

explore

hotspot

leisure time